title: Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.).
abstract: A Phase I trial of carboplatin therapy was performed on patients with locally advanced non-small cell lung cancer who had been previously treated with cisplatin, mitomycin and a vinca aklaloïd. This was administered as a daily bolus infusion or as a continuous infusion for 6 weeks with concurrent daily thoracic radiation. All patients had to be objective responders or to show no change after chemotherapy. The carboplatin was started at 10 mg/m2 per day, and increased to 15 mg/m2 per day and 20 mg/m2 per day, if treatment was feasible in successive cohorts of at least six patients. The radiation therapy consisted of 62-66 Gray on the tumor and the ipsilateral mediastinal nodes, 50 Gray on the mediastinum and 40-45 Gray on the supraclavicular lymph nodes. Twenty-nine patients took part in this study. Thrombocytopenia was the principal dose-limiting toxicity, with 15 mg/m2 per day of bolus or continuous infusion. Other toxicities included a fall in haemoglobin level, a fall in white-blood cell count, nausea and vomiting. The median survival time was 12 months, but the response rate cannot be determined among patients selected on the basis of response to chemotherapy. The recommended Phase II dose for patients previously treated with cisplatin containing chemotherapy, is 10 mg/m2 per day of either a bolus or continuous infusion.
authors.affiliation: Service d'oncologie respiratoire, Hopital Sainte-Marguerite, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: J P
authors.initials: JP
authors.lastname: Kleisbauer
authors.forename: G
authors.initials: G
authors.lastname: Robinet
authors.forename: J
authors.initials: J
authors.lastname: Clavier
authors.forename: R
authors.initials: R
authors.lastname: Poirier
authors.forename: A
authors.initials: A
authors.lastname: Vernenegre
authors.forename: F
authors.initials: F
authors.lastname: Bonnaud
authors.forename: A
authors.initials: A
authors.lastname: Taytard
authors.forename: D
authors.initials: D
authors.lastname: Paillotin
authors.forename: P
authors.initials: P
authors.lastname: Pommier De Santi
authors.forename: J R
authors.initials: JR
authors.lastname: Barriere
authors.forename: T
authors.initials: T
authors.lastname: Pignon
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014751:Vindesine / Q000008:administration & dosage; D000077235:Vinorelbine
chemical_list: D011838:Radiation-Sensitizing Agents; D016685:Mitomycin; D014747:Vinblastine; D016190:Carboplatin; D002945:Cisplatin; D000077235:Vinorelbine; D014751:Vindesine